Angiotensin‐Converting Enzyme Inhibitors and Alzheimer's Disease Progression in Older Adults: Results from the Réseau sur la Maladie d'Alzheimer Français Cohort
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objectives: To assess whether angiotensin‐converting enzyme inhibitor ( ACE ‐I) treatment is associated with less cognitive decline in older adults with Alzheimer's disease ( AD ) than in those using other hypertensive or no drugs. Design: Four‐year prospective multicenter cohort study with a biannual assessment. Setting: Memory clinics from 16 university hospitals in France. Participants: Community‐dwelling older adults with mild to moderate AD (N = 616). Measurements: Participants were stratified into four groups according to type and duration of antihypertensive drug treatment. Cognitive decline was assessed using the Mini‐Mental State Examination ( MMSE ). Linear mixed‐effects models were used to assess differences in decline in MMSE score between the four groups. Hypertension at each visit was included in the model. Results: Sixty‐one participants had used ACE ‐Is continuously, 57 had used them intermittently, 189 had used other antihypertensive drugs, and 309 never used any antihypertensive drugs. Continuous ACE ‐Is users had a 4‐year decline in MMSE of 6.4 ± 1.6 points ( P < .001), intermittent ACE ‐Is users of 7.9 ± 1.1 points ( P < .001), continuous or intermittent users of other antihypertensive drugs of 8.8 ± 0.7 points ( P < .001), and never‐users of 10.2 ± 0.6 points ( P < .001). MMSE decline between the four groups was significantly different (adjusted P = .02). In subgroup analysis, the 118 (19.2%) participants who had continuously or intermittently used ACE ‐Is had a significant difference in 4‐year MMSE decline from the 498 (80.8%) who had never used ACE ‐Is (7.5 ± 0.9 vs 9.7 ± 0.4; P = .03). Conclusion: The use of ACE ‐Is in older adults with AD is associated with a slower rate of cognitive decline independent of hypertension. Future research is needed to explore the role of ACE ‐Is in long‐term AD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 1×
“Three found positive results in term of prevention of dementia(5) or cognitive decline(6,7) in adults without dementia, whereas others reported nonsignificant findings.(8,9) In longitudinal observational studies, conflicting results have also been found.”
ResultCardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189 · cited 1×
“The presence of CVRF was considered independently of the other comorbidities because of its association with ACE-I treatment and because CVRFs are well-known risk factors for developing dementia.(22) JAGS SEPTEMBER 2013–VOL.”
BackgroundRozzini, L., Chilovi, B. V., Bertoletti, E., Conti, M., Rio, I. D., Trabucchi, M., & Padovani, A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1523 · Cited by 93 · cited 1×
“Furthermore, stabilization of cognitive function by ACE-Is has been reported in individuals with amnestic mild cognitive impairment.(12) The effect of antihypertensive therapy with ACE-Is on cognitive decline in individuals with AD is still unknown.”
Method
Cited by
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Sarcopenia and Cognitive Decline in Older Adults: Targeting the Muscle–Brain Axis
Arosio, B., Calvani, R., Ferri, E., Coelho-Junior, H. J., Carandina, A., Campanelli, F., Ghiglieri, V., Marzetti, E., & Picca, A. (2023) · Nutrients · doi:10.3390/nu15081853 · Cited by 165
Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors
Nestor, J., Arinuma, Y., Huerta, T. S., Kowal, C., Nasiri, E., Kello, N., Fujieda, Y., Bialas, A., Hammond, T., Sriram, U., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180776 · Cited by 146
“ACE inhibitors block neurotoxic DNRAbs 2559 servational studies in AD patients also suggest benefit from ACE inhibition (Hajjar et al., 2008; Soto et al., 2013; Yasar et al., 2013; de Oliveira et al., 2014, 2018; O’Caoimh et al., 2014; Zhuang et al., 2016).”
BackgroundLi, Y., Zhang, Z., Deng, L., Bai, F., Shi, Y., Yu, H., Xie, C., Yuan, Y., & Zhang, Z. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.06.026 · Cited by 15
Metadata
- Authors
- Soto, M. E., Abellan van Kan, G., Nourhashemi, F., Gillette‐Guyonnet, S., Cesari, M., Cantet, C., Rolland, Y., & Vellas, B.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2013-09
- Volume
- 61
- Issue
- 9
- Pages
- 1482-1488
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2054031839
- Cited by
- 80
- References
- 4
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.